Variant:
rs5030656 at chr22:42524176 in CYP2D6 (VIP)

Alleles (on + chromosomal strand)
CTT > -
Amino Acid Translation
LysAla230Ala
Alternate Names:
c.688_690del3, c.841_843del3, g.21914745_21914747del3, g.27341_27343del3, g.2774_2776del3, g.7706_7708del3
Haplotypes
This variant is used to determine: CYP2D6*9

VIP Variant in CYP2D6

The deletion of amino acid K281 can be caused either by CYP2D6 2613-2615 del AGA or _CYP2D_6 2615-2617 del AAG [Articles:1844820, 2574001]. In vitro work on this mutation in HepG2 cells indicated that this variant exhibited reduced function, although without changing the Km of bufuralol, debrisoquine, or sparteine, which suggests that the expression level of the protein may be altered by this mutation. CYP2D6 2613-2615 del AGA is the definitive variation for the CYP2D6*9 haplotype [Article:10634130]. Further in vivo work with this polymorphism has cast doubt on whether or not it leads to reduced function [Article:8101460].

Note: The CYP2D6 gene is found on the minus chromosomal strand. Please note that for standardization, the PharmGKB presents all allele base pairs on the positive chromosomal strand, therefore the alleles within our variant annotations will differ (in a complementary manner) from those in this VIP summary that are given on the minus strand as reported in the literature.

Key Publications:
Drugs / Other Molecules
Diseases Cystic Fibrosis Depression Hypertension Neoplasms Pain Parkinson Disease Schizophrenia
Phenotype Datasets Hot flashes in tamoxifen patients
Lipid measurements in tamoxifen study
Lipid measurements in tamoxifen study - set 2
Meperidine N-demethylation by human CYP450 isoforms
Metabolism of yohimbine by human CYP450 isoforms
Patient responses to tamoxifen
Pharmacokinetics of Tamoxifen at 4 months
Thyroid binding globulin in tamoxifen patients

Appendix

CYP2D6: 2613-2615 del AGA or 2615-2617 del AAG

Genomic Variant & GenBank ID: 4232-4234 del AGA on M33388 or 4234-4236 del AAG on M33388
mRNA Variant & GenBank ID: 839-841 del AGA on X08006 or 841-843 del AAG on X08006
Protein Variant & GenBank ID: deletes K281 on AAH75024
GoldenPath Position: chr22:40854122-40854124 or chr22:40854120-40854122 on hg 18

Connected Drugs

Connected Diseases

Publications related to rs5030656 at chr22:42524176: 3

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics. 1999. Gaedigk A, et al. [Article:10634130@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics. 1993. Broly F, et al. [Article:8101460@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics. 1991. Tyndale R, et al. [Article:1844820@PubMed]

Cross-References

UCSC Golden Path:
chr22:42524176
dbSNP:
rs5030656
ALFRED:
SI015496Z

Common Searches

PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.